Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇩🇪DE · Life Sciences#1915K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.5K to 15K🎙 Weekly cadence·53 episodes·Last published 5mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
5K to 30K🇩🇪100% - Active Followers
Loyal subscribers who consistently listen
1.5K to 9K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
Ken Harris: Why AI and automation are CGT’s next inflection point
Jan 27, 2026
1h 03m 25s
Joe DePinto: Why advanced therapies need a new delivery model
Jan 13, 2026
1h 04m 41s
Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy
Dec 16, 2025
55m 35s
John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later
Dec 3, 2025
50m 11s
Warner Biddle: Building a commercial model for CAR-T in autoimmune care
Sep 2, 2025
40m 41s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 1/27/26 |  Ken Harris: Why AI and automation are CGT’s next inflection point✨ | AIautomation+5 | Ken Harris | Omnia BioAmazon Web Services | — | AIautomation+8 | — | 1h 03m 25s | |
| 1/13/26 |  Joe DePinto: Why advanced therapies need a new delivery model✨ | advanced therapiesdelivery model+4 | Joe DePinto | McKesson | — | advanced therapiesdelivery model+5 | — | 1h 04m 41s | |
| 12/16/25 |  Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy✨ | myelomaCAR-T therapy+4 | Jonathan Gluck | Ori BiotechAn Exercise in Uncertainty | — | myelomaCAR-T therapy+5 | — | 55m 35s | |
| 12/3/25 |  John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later✨ | advanced therapiesmanufacturing techniques+4 | John Khoury | Project Farma | — | CGTmanufacturing risk+3 | — | 50m 11s | |
| 9/2/25 |  Warner Biddle: Building a commercial model for CAR-T in autoimmune care✨ | CAR-T therapiesautoimmune disease+4 | Warner Biddle | Kyverna Therapeutics | — | CAR-Tautoimmune care+5 | — | 40m 41s | |
| 8/12/25 |  Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success✨ | cell therapiesCGT trials+4 | Lavakumar Karyampudi | Moffitt Cancer Center | — | cell therapiesCGT+5 | — | 1h 00m 07s | |
| 7/15/25 |  Henrik Andersen: How smart planning helps CGT scale further, faster✨ | cell therapymanufacturing strategy+4 | Henrik Andersen | Bristol Myers Squibb | — | cell therapiesautomation+4 | — | 54m 20s | |
| 7/1/25 |  Arsalan Arif: Investor confidence in advanced therapies is critical for long-term success✨ | biotechinvestor confidence+4 | Arsalan Arif | Endpoints NewsFinancial Times | — | biotechinvestor sentiment+4 | — | 47m 48s | |
| 6/17/25 |  Julie Allickson: How early automation strategies reduce costs and improve patient access✨ | automationregenerative medicine+4 | Dr. Julie Allickson | Mayo ClinicCenter for Regenerative Biotherapeutics | — | automationregenerative medicine+5 | — | 48m 37s | |
| 6/3/25 |  Aaron Vernon: Designing scalable cell therapy manufacturing from day one (part 2)✨ | cell therapymanufacturing+3 | Aaron Vernon | Quell Therapeutics | — | cell therapymanufacturing systems+4 | — | 44m 07s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/23/25 |  Aaron Vernon: Designing scalable cell therapy manufacturing from day one (part 1) | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for a two-part discussion on building robust and scalable cell therapy manufacturing systems. Together they explore how applying principles like the Theory of Constraints, designing smarter facility layouts, and implementing digital systems can reduce bottlenecks and improve throughput.Aaron brings over 20 years of experience leading manufacturing, engineering and supply chain operations across biologics and cell therapy. We’re grateful for his insights as the industry works to deliver more consistent, cost-effective therapies to patients at scale.Learn more: https://www.linkedin.com/in/aaronvernon/ | — | ||||||
| 11/25/24 |  Amritha Jaishankar: Advancing data integration and decentralized manufacturing for CGT access | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Amritha Jaishankar, Executive Director of the Cell and Gene Therapy Center at IQVIA, to discuss how data integration and decentralized manufacturing are reshaping access to advanced therapies. Amritha shares her insights on how to overcome systemic challenges in cell and gene therapy, including data silos, workforce gaps, and manufacturing inefficiencies. Together, they explore the transformative potential of community sites, digital platforms and collaborative partnerships in driving scalability, improving affordability of CGTs, and expanding their access worldwide. Learn more: https://www.linkedin.com/in/amrithajaishankar/ | — | ||||||
| 11/5/24 |  Boro Dropulić: Simplifying CAR-T workflows will break down barriers to patient access | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Boro Dropulić, CEO of Vector Biomed and Executive Director at Caring Cross. Boro shares his vision of how decentralized manufacturing, low-cost vector production, and open-source workflows can make cell and gene therapies more accessible worldwide. They also discuss the role of digital technologies, partnerships, and innovative processes in overcoming industry bottlenecks, driving down costs, and expanding this access. Learn more about Boro on LinkedIn | — | ||||||
| 10/8/24 |  Michael Krajewski: How does the Theory of Constraints apply to CGT manufacturing? | In this episode of the Ori Spotlight Podcast, Jason Foster is joined by Michael Krajewski, Director at Stand Back and an expert in engineering and scaling operations. Michael, with his background in aeronautics, brings a unique perspective on the Theory of Constraints and its role in CGT manufacturing processes. Michael and Jason dive into the complex dynamics of bottlenecks and discuss how understanding constraints can pave the way for growth – without compromising efficiency. Together, they explore how manufacturing lessons from other industries can address the limitations faced by cell therapy today, and what it takes to streamline complex, regulated processes. Learn more about Michael: https://www.linkedin.com/in/michael-krajewski/ | — | ||||||
| 6/25/24 |  Carl Schoellhammer: viability is the crucial third pillar in CGT | In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/ | — | ||||||
| 6/4/24 |  Anshul Mangal: Unlocking scale, automation, digitalization, and standardization in CGT | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic planning, and the role of digitalization in improving efficiency and reducing costs. Together they also highlight the potential of distributed manufacturing and the evolution of regulatory standards. Anshul Mangal is a biotech entrepreneur and executive, leading Project Farma and Precision for Medicine's Manufacturing Solutions. He has pioneered the industrialization of early cell and gene therapies. Anshul also serves on the boards of the Alliance for Regenerative Medicines, Alliance for mRNA Medicines, and IQHQ, driving advancements in next-generation medicines. Learn more about Anshul Mangal: https://www.linkedin.com/in/amangal/ | — | ||||||
| 5/14/24 |  Omkar Kawalekar: technology will unlock scalability and patient access | In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufacturing challenges and developing advanced therapies at scale. Their conversation covers key industry hurdles like supply chain optimization and the strategic planning necessary for bringing innovative treatments to market – offering insights into how the industry can achieve commercial viability and widespread patient access to CGTs. Learn more about Omkar: https://www.linkedin.com/in/omkar-kawalekar-7406887/ | — | ||||||
| 4/22/24 |  Joe DePinto: Bridging growth and accessibility within CGTs | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therapy manufacturing and supply chains. Together they also highlight the importance of collaborative partnerships and digital innovations to enhance access and streamline processes within the CGT sector. Joe DePinto is a strategic and operational leader at McKesson, focusing on establishing the company as a market leader in cell, gene, and advanced therapies. With an extensive background in biotech and pharmaceuticals, Joe has helped companies pioneer advanced solutions in speciality healthcare. Learn more about Joe DePinto: https://www.linkedin.com/in/joe-depinto-4a5b7b11/details/experience/ | — | ||||||
| 3/11/24 |  Matthew Hewitt: scalability is a collective problem | In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to discuss why industry collaboration is needed to experience the true impact of advanced therapies and develop them at a commercial scale. Together they also highlight the role of technology in closing, automating and scaling manufacturing processes. Matthew has over 10 years of experience in the CGT sector, contributing to the advancement of CGTs across research and commercialization. As a member of our Strategic Advisory Board we're grateful for Matthew's insights as we work towards enabling widespread patient access to CGTs. Learn more about Matthew Hewitt: https://www.linkedin.com/in/matthewmhewitt/ | — | ||||||
| 2/19/24 |  Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility | In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene therapy (CGT) industry. LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensive background in life sciences consulting, share their insights on the importance of early investment in manufacturing processes to ensure that groundbreaking therapies can be delivered to patients efficiently and on a large scale. Together they explore the intricacies of CGT production, the significance of early-stage manufacturing considerations, and their vision for making advanced therapies more accessible to those in need. Learn more about: Jeff Holder - https://www.linkedin.com/in/jeff-holder-ph-d-7a391087 Adam Siebert - https://www.linkedin.com/in/adam-siebert-8772b327/ | — | ||||||
| 1/29/24 |  Jim Faulkner: Why unaffordable therapy success is worse than failure... | In this episode of Ori Spotlight Podcast, we welcome Jim Faulkner, PhD, Independent Consultant at JDB BioConsulting and former SVP of Product Delivery at Autolus. Jim brings a wealth of experience from his remarkable career in biopharmaceutical development and his journey in the industry is marked by significant contributions, particularly in pioneering cell therapy at GSK. The episode offers a deep dive into the evolving challenges in CGT manufacturing – centering on the critical challenges of scalability and commercial viability in CGTs – and sheds light on the unique demands and opportunities in the sector. Learn more about Jim: https://www.linkedin.com/in/drjimfaulkner/ | — | ||||||
| 1/8/24 |  Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End? | In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies. Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments. Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/ | — | ||||||
| 7/18/23 |  Tim Hunt: leading CGT with education and community | We’re joined by Tim Hunt, CEO of Alliance for Regenerative Medicine (ARM). As an international advocacy organization, ARM is a global voice within the cell and gene therapy sector. They champion the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society as well as facilitating influential exchanges on policies and practices, and advances in narrative with data and analysis. In this episode, Tim and Jason C. Foster discuss why it is important to put the patient first and where we should be focusing our attention to reduce the cost of goods and improve the accessibility of cell and gene therapies. Tim also offers his advice for people and companies working in the CGT space. Learn more about Tim: https://www.linkedin.com/in/timhunt100/ | — | ||||||
| 6/27/23 |  Vered Caplan: why yesterday’s thinking is not going to solve today’s problems | We’re joined by Vered Caplan, CEO of Orgenesis, as she shares her insights into the cell and gene therapy sector. With a background in engineering and business, Vered found her passion in the cell and gene therapy industry. She founded Orgenesis with a mission to bring innovative therapies to patients, by leveraging cutting-edge science to create a more efficient, scalable, and affordable pathway to patients. In this episode, Vered discusses: 🧬 The need for greater adoption of technology to overcome manufacturing challenges of advanced therapies 🧬 Why digital is the key to tailoring manufacturing processes to the individual needs of patients 🧬 How industry partnerships support the scalability of therapy products Learn more about Vered: https://www.linkedin.com/in/vered-caplan-4366928/ | — | ||||||
| 6/13/23 |  Daniel Gibson: improving patient access to cell therapies | On this episode of the Ori Spotlight Podcast, we're joined by Daniel Gibson Director of Cell and Gene Therapy Services at Anthony Nolan. Anthony Nolan is a charity on a mission to improve the lives of people with blood cancer and blood disorders, by connecting patients and stem cell donors, funding research into cell therapies, and supporting patients along their transplant journey. Together, Jason and Daniel discuss the barriers limiting widespread patient access to cell therapies, why we need to adapt manufacturing processes, and how regulation can ensure scaleable development. Read more about Anthony Nolan’s work: https://www.anthonynolan.org/ | — | ||||||
Showing 25 of 52
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.